Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04077-4
Abstract: Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment… read more here.
Keywords: relapsed refractory; hodgkin lymphoma; treatment; refractory chl ... See more keywords